The efficacy of concurrent chemoradiation for locally advanced non-small cell lung cancer prospectively treated at Cho Ray hospital, Vietnam, from 3/2009 to 3/2012

Tuan Anh Le

doi:10.18453/rosdok_id00001669

Tuan Anh Le

The efficacy of concurrent chemoradiation for locally advanced non-small cell lung cancer prospectively treated at Cho Ray hospital, Vietnam, from 3/2009 to 3/2012

Universität Rostock, 2015

https://doi.org/10.18453/rosdok_id00001669

Abstract: From 1/3/2009 to 1/3/2012, 1158 patients were diagnosed of lung cancers at Cho Ray hospital, included adenocarcinoma (64.3%), squamous cell carcinoma (11.3%), small cell (4.9%) and others. In NSCLC, 38.4% were in stage III and 60 (14.2%)were selected to receive weekly Paclitaxel–Carboplatin concurrently with chest radiotherapy. Common severe toxicities included esophagitis (23.3%) and fatigue (23.3%). Response rate was 57.2%; median of overall and progression-free survival were 14.4 and 10.8 months. Pretreatment performance status and weight loss were two only significant prognostic factors.

Dissertation Freier Zugang

Titel:

The efficacy of concurrent chemoradiation for locally advanced non-small cell lung cancer prospectively treated at Cho Ray hospital, Vietnam, from 3/2009 to 3/2012

Beteiligte Personen:

Tuan Anh Le[VerfasserIn]
	1060675501
Guido Hildebrandt , Prof. Dr. med.[AkademischeR BetreuerIn]
	Universitätsmedizin Rostock, Klinik und Poliklinik für Strahlentherapie
Johann Christian Virchow , Prof. Dr. med.[AkademischeR BetreuerIn]
	136807801
	Universitätsmedizin Rostock, Zentrum für Innere Medizin, Medizinische Klinik I, Abteilung Pneumologie
Rolf-Dieter Kortmann , Prof. Dr. med.[AkademischeR BetreuerIn]
	Universität Leipzig, Klinik für Strahlentherapie

Beteiligte Körperschaften:

Universität Rostock, Universitätsmedizin[Grad-verleihende Institution]
	1029510660

Zusammenfassung:

From 1/3/2009 to 1/3/2012, 1158 patients were diagnosed of lung cancers at Cho Ray hospital, included adenocarcinoma (64.3%), squamous cell carcinoma (11.3%), small cell (4.9%) and others. In NSCLC, 38.4% were in stage III and 60 (14.2%)were selected to receive weekly Paclitaxel–Carboplatin concurrently with chest radiotherapy. Common severe toxicities included esophagitis (23.3%) and fatigue (23.3%). Response rate was 57.2%; median of overall and progression-free survival were 14.4 and 10.8 months. Pretreatment performance status and weight loss were two only significant prognostic factors. [Englisch]

Dokumenttyp:

Dissertation

Einrichtung:

Universitätsmedizin

Sprache:

Englisch

Sachgruppe der DNB:

610 Medizin, Gesundheit

Veröffentlichung /
Entstehung:

Rostock: Universität Rostock

2015

Identifikatoren: